학술논문

Huntington’s disease cerebrospinal fluid seeds aggregation of mutant huntingtin
Document Type
article
Source
Molecular Psychiatry. 20(11)
Subject
Biomedical and Clinical Sciences
Biological Psychology
Clinical and Health Psychology
Clinical Sciences
Psychology
Neurosciences
Neurodegenerative
Brain Disorders
Orphan Drug
Huntington's Disease
Rare Diseases
2.1 Biological and endogenous factors
Aetiology
Neurological
Animals
Cells
Cultured
Female
Humans
Huntingtin Protein
Huntington Disease
Male
Microscopy
Electron
Mutation
Nerve Tissue Proteins
Peptides
Protein Aggregation
Pathological
Rats
Rats
Transgenic
Transfection
Biological Sciences
Medical and Health Sciences
Psychology and Cognitive Sciences
Psychiatry
Clinical sciences
Biological psychology
Clinical and health psychology
Language
Abstract
Huntington's disease (HD), a progressive neurodegenerative disease, is caused by an expanded CAG triplet repeat producing a mutant huntingtin protein (mHTT) with a polyglutamine-repeat expansion. Onset of symptoms in mutant huntingtin gene-carrying individuals remains unpredictable. We report that synthetic polyglutamine oligomers and cerebrospinal fluid (CSF) from BACHD transgenic rats and from human HD subjects can seed mutant huntingtin aggregation in a cell model and its cell lysate. Our studies demonstrate that seeding requires the mutant huntingtin template and may reflect an underlying prion-like protein propagation mechanism. Light and cryo-electron microscopy show that synthetic seeds nucleate and enhance mutant huntingtin aggregation. This seeding assay distinguishes HD subjects from healthy and non-HD dementia controls without overlap (blinded samples). Ultimately, this seeding property in HD patient CSF may form the basis of a molecular biomarker assay to monitor HD and evaluate therapies that target mHTT.